Skip to main
Genetic science research
George Mason University
News

Petricoin conducting protein pathway activation based signaling mapping of head and neck cancers

Elizabeth Grisham

Emanuel Petricoin, Co-Director, Center for Applied Proteomics and Molecular Medicine (CAPMM), received funding for the project: “Protein Pathway Activation Based Signaling Mapping of Head And Neck Cancers.”

Researchers with George Mason’s Center for Applied Proteomics and Molecular Medicine will receive laser microdissected tumor samples from banked Formalin-Fixed Paraffin-Embedded (FFPE) clinical biopsy samples from patients with HPV‐positive Head and Neck Cancers who were treated for newly diagnosed disease.

The researchers will utilize comprehensive reverse‐phase protein microarray (RPPA)-based analysis of 170 pre‐specified proteins and phosphoproteins involved in inflammation pathways, DNA damage and repair pathways, reactive oxygen species pathways, mitophagy pathways, cell survival and apoptosis pathways. 

Petricoin received $63,640 from Inova Healthcare for this research. Funding began in May 2024 and will end in May 2025.

* The programs and services offered by George Mason University are open to all who seek them. George Mason does not discriminate on the basis of race, color, religion, ethnic national origin (including shared ancestry and/or ethnic characteristics), sex, disability, military status (including veteran status), sexual orientation, gender identity, gender expression, age, marital status, pregnancy status, genetic information, or any other characteristic protected by law. After an initial review of its policies and practices, the university affirms its commitment to meet all federal mandates as articulated in federal law, as well as recent executive orders and federal agency directives.